ARQT — Arcutis Biotherapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1787306 ·
Last close
$24.49
Market Cap
$3.08B
52W High
$31.77
52W Low
$19.30
ADV30
2,997,071
Next earnings
2026-10-27
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 129,861,000 | 118,922,000 | 16,429,000 | 15,009,000 | 488,537,000 | 34,121,000 | 267,958,000 |
| Mar 2026 | 105,398,000 | 95,614,000 | -9,089,000 | -11,295,000 | 460,003,000 | 34,762,000 | 270,355,000 |
| Dec 2025 | 129,503,000 | 117,815,000 | 18,387,000 | 17,395,000 | 432,973,000 | 42,907,000 | 243,494,000 |
| Sep 2025 | 99,219,000 | 90,534,000 | 8,526,000 | 7,410,000 | 370,977,000 | 47,120,000 | 212,904,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$39,309,000
Investing CF
$-85,982,000
Financing CF
$8,255,000
CapEx
$-15,686,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.21
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,134,370,000
Inventory
$38,879,000
Receivables
$155,162,000
ST Investments
$204,431,000
EBIT TTM
$43,144,000
Pretax Income TTM
$29,298,000
Interest Exp TTM
$13,846,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$463,980,992
EBITDA
$36,503,000
Free Cash Flow
$21,685,376
Enterprise Value
$2,877,737,472
Total Cash
$238,552,000
Total Debt
$114,137,000
Shares Out
125,691,961
Trailing EPS
$0.22
Book Value
$1.76
ROE
15.9%
ROA
5.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 376,072,000 | -12,227,000 | -16,141,000 | 432,973,000 | 243,494,000 | 189,479,000 | -5,625,000 |
| Dec 2024 | 196,542,000 | -128,397,000 | -140,039,000 | 348,889,000 | 191,348,000 | 157,541,000 | -112,158,000 |
| Dec 2023 | 59,606,000 | -241,101,000 | -262,140,000 | 341,365,000 | 252,698,000 | 88,667,000 | -247,057,000 |
| Dec 2022 | 3,686,000 | -301,627,000 | -311,458,000 | 449,274,000 | 239,693,000 | 209,581,000 | -257,715,000 |
TTM Snapshot
Revenues TTM
$415,624,000
NetIncome TTM
$-2,376,000
OpCashFlow TTM
—
Assets (Latest)
$460,003,000
Forward EPS
$1.30
Max Pain — expiry 2026-10-16
max pain strike: $27.50 · spot: $26.41 · call oi: 4,649 · put oi: 298
Expected Move to 2026-10-16:
±$2.95
(11.17%) —
implied range
$23.46 –
$29.36
· ATM straddle on $27.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DYN | Dyne Therapeutics, Inc. | $3.06B | $16.37 | — |
| AMLX | Amylyx Pharmaceuticals, Inc. | $3.03B | $27.20 | — |
| RCUS | Arcus Biosciences, Inc. | $3.00B | $23.83 | — |
| ELVN | Enliven Therapeutics, Inc. | $2.98B | $40.63 | — |
| VKTX | Viking Therapeutics, Inc. | $3.23B | $27.73 | — |
News headlines (Yahoo Finance, 1h cache)
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical
2026-10-09 12:00 · Yahoo
Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award
2026-10-06 12:19 · Yahoo
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-02 20:00 · Yahoo
Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options
2026-09-29 13:15 · Yahoo
Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last?
2026-09-17 14:38 · Yahoo
Here’s What Arcutis’ CEO Said at the Morgan Stanley Healthcare Conference That Made the Stock Jump 11%
2026-09-17 07:20 · Yahoo
Arcutis Biotherapeutics (ARQT) Faces A Valuation Test, Is It Still A Bargain?
2026-08-28 01:07 · Yahoo
Arcutis (ARQT) Q2 2026 Earnings Call Transcript
2026-08-12 21:28 · Yahoo
AXT Inc. (AXTI) Climbs 16% on S&P 600 Addition
2026-09-21 20:00 · Yahoo
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen
2026-08-27 08:27 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.